Jianda Kyushu

GenAns Biotech (Jianda Jiuzhou) is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative gene therapies for central nervous system (CNS) and ophthalmic disorders. Founded in 2022 by Dr. Luo Minmin, Director of the Beijing Institute for Brain Science and Brain-Inspired Intelligence, the company utilizes advanced optogenetics and chemogenetics platforms to address refractory conditions. Its lead candidate, GA001, is an AAV-based gene therapy for retinitis pigmentosa that has received IND approval from both the FDA and China's CDE. The company's pipeline also includes GA002, a first-in-class chemogenetic therapy for drug-resistant epilepsy, alongside programs for chronic pain, depression, and brain tumors.